Clinical Report: Efficacy of Glofitamab in Sequential Treatment Approaches
Overview
This study evaluates the efficacy of Glofitamab in patients with relapsed/refractory B-cell lymphoma through various sequential treatment strategies.
Background
Relapsed or refractory B-cell lymphoma presents significant treatment challenges, with a considerable proportion of patients not achieving long-term remission. Glofitamab, a bispecific antibody, offers a novel therapeutic option, particularly in cases where traditional therapies have failed.
Data Highlights
No numerical data available in the provided source material.
Key Findings
Glofitamab demonstrated controllable safety and durable anti-tumor activity in three clinical scenarios.
Patients receiving Glofitamab after CAR-T therapy failure experienced clinical benefits.
The study included 24 patients with various types of relapsed/refractory B-cell lymphoma.
Sequential treatment strategies involving Glofitamab were explored, including as a rescue therapy and bridging therapy.
Clinical Implications
Clinicians should consider Glofitamab in sequential treatment strategies for patients with relapsed/refractory B-cell lymphoma.
Conclusion
Further studies are warranted to establish optimal treatment sequences for Glofitamab.
